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Abstract: Importance: Immunotherapy with checkpoint inhibitors targeting the PD-1 (programmed cell
death 1) axis has brought notable progress in patients with non–small cell lung cancer (NSCLC) and other
cancers. However, autoimmune toxic effects are frequent and poorly understood, making it important to
understand the pathophysiologic processes of autoimmune adverse effects induced by checkpoint inhibitor
therapy. Objective: To gain mechanistic insight into autoimmune skin toxic effects induced by anti–PD-1
treatment in patients with non–small cell lung cancer. Design, Setting, and Participants: This prospective
cohort study was conducted from July 1, 2016, to December 31, 2018. Patients (n = 73) with non–small
cell lung cancer who received anti–PD-1 therapy (nivolumab or pembrolizumab) were recruited from 4
different centers in Switzerland (Kantonsspital St Gallen, Spital Grabs, Spital Wil, and Spital Flawil).
Peripheral blood mononuclear cells, tumor biopsy specimens and biopsies from sites of autoimmune skin
toxic effects were collected over a 2-year period, with patient follow-up after 1 year. Main Outcomes
and Measures: Response to treatment, overall survival, progression-free survival, and development of
autoimmune toxic effects (based on standard laboratory values and clinical examinations). Results: Of
the cohort of 73 patients with NSCLC (mean [SD] age, 68.1 [8.9] years; 44 [60%] men), 25 (34.2% [95%
CI, 24.4%-45.7%]) developed autoimmune skin toxic effects, which were more frequent in patients with
complete remission or partial remission (68.2% [95% CI, 47.3%-83.6%]) than those with progressive or
stable disease (19.6% [95% CI, 11.0%-32.5%]) (￿2 = 14.02, P < .001). Nine T-cell antigens shared between
tumor tissue and skin were identified. These antigens were able to stimulate CD8+ and CD4+ T cells in
vitro. Several of the antigen-specific T cells found in blood samples were also present in autoimmune skin
lesions and lung tumors of patients who responded to anti–PD-1 therapy. Conclusions and Relevance:
These findings highlight a potential mechanism of checkpoint inhibitor–mediated autoimmune toxic effects
and describe the association between toxic effects and response to therapy; such an understanding will help
in controlling adverse effects, deciphering new cancer antigens, and further improving immunotherapy.
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IMPORTANCE Immunotherapy with checkpoint inhibitors targeting the PD-1 (programmed
cell death 1) axis has brought notable progress in patients with non–small cell lung cancer
(NSCLC) and other cancers. However, autoimmune toxic effects are frequent and poorly
understood, making it important to understand the pathophysiologic processes of
autoimmune adverse effects induced by checkpoint inhibitor therapy.
OBJECTIVE To gain mechanistic insight into autoimmune skin toxic effects induced by
anti–PD-1 treatment in patients with non–small cell lung cancer.
DESIGN, SETTING, AND PARTICIPANTS This prospective cohort studywas conducted from July
1, 2016, to December 31, 2018. Patients (n = 73) with non–small cell lung cancer who received
anti–PD-1 therapy (nivolumab or pembrolizumab) were recruited from 4 different centers in
Switzerland (Kantonsspital St Gallen, Spital Grabs, Spital Wil, and Spital Flawil). Peripheral
bloodmononuclear cells, tumor biopsy specimens and biopsies from sites of autoimmune
skin toxic effects were collected over a 2-year period, with patient follow-up after 1 year.
MAIN OUTCOMES ANDMEASURES Response to treatment, overall survival, progression-free
survival, and development of autoimmune toxic effects (based on standard laboratory values
and clinical examinations).
RESULTS Of the cohort of 73 patients with NSCLC (mean [SD] age, 68.1 [8.9] years; 44 [60%]
men), 25 (34.2% [95% CI, 24.4%-45.7%]) developed autoimmune skin toxic effects. Of the
73 patients with NSCLC, 25 (34.2% [95% CI, 24.4%-45.7%]) developed autoimmune skin
toxic effects, which were more frequent in patients with complete remission or partial
remission (68.2% [95% CI, 47.3%-83.6%]) than those with progressive or stable disease
(19.6% [95% CI, 11.0%-32.5%]) (χ2 = 14.02, P < .001). Nine T-cell antigens shared between
tumor tissue and skin were identified. These antigens were able to stimulate CD8+ and CD4+
T cells in vitro. Several of the antigen-specific T cells found in blood samples were also present
in autoimmune skin lesions and lung tumors of patients who responded to anti–PD-1 therapy.
CONCLUSIONS AND RELEVANCE These findings highlight a potential mechanism of checkpoint
inhibitor–mediated autoimmune toxic effects and describe the association between toxic
effects and response to therapy; such an understanding will help in controlling adverse
effects, deciphering new cancer antigens, and further improving immunotherapy.
JAMA Oncol. doi:10.1001/jamaoncol.2019.0402
Published online April 25, 2019.
Editorial
Related article
Supplemental content
Author Affiliations:Author
affiliations are listed at the end of this
article.
Corresponding Author: Lukas Flatz,
MD, Department of Dermatology and
Allergology, Kantonsspital St Gallen,
Rorschacher Strasse 95,
9007 St Gallen, Switzerland
(Lukas.Flatz@kssg.ch).
Research
JAMAOncology | Brief Report
(Reprinted) E1
© 2019 American Medical Association. All rights reserved.
Downloaded From: https://jamanetwork.com/ by a UZH Hauptbibliothek / Zentralbibliothek Zuerich User  on 06/07/2019
C ancer immunotherapy with checkpoint inhibitors hasbeenreportedto improvesurvival forpatientswithnon–small cell lung cancer (NSCLC).1-3 However, the auto-
immune toxic effects of checkpoint inhibitors are frequent,
with immune-mediated adverse effects of any grade occur-
ring inapproximately30%ofpatientsand toxiceffectsofgrade
3,4,or5occurring inupto 10%ofpatients.1Thecausesof these
events remain elusive. We studied a prospective cohort of 73
patients with NSCLC receiving anti–PD-1 (programmed cell
death 1) therapy to gain insight into the pathophysiologic
processes of autoimmune skin toxic effects.
Methods
Clinical Sample Collection
A prospective cohort study of patients with NSCLC who re-
ceived anti–PD-1 treatmentwas conducted in 4 different cen-
ters inSwitzerland (Kantonsspital StGallen, SpitalGrabs, Spital
Wil, andSpital Flawil) fromJuly 1, 2016, toDecember 31, 2018.
The study received ethical approval from the Ethikkommis-
sionOstschweiz. Informed consentwas obtained from all pa-
tients. Peripheral bloodmononuclear cells (PBMCs) and lung
tumor and skin samples were collected for analyses, with
patient follow-up after 1 year.
T-Cell Stimulation Assays and T-Cell Receptor Analysis
Peripheral bloodmononuclear cellswere stimulatedwithpep-
tidepools at a concentrationof 2ug/mL/peptide.After 10days
of culture, cells were restimulated with peptide pools for
6 hours and stained for CD3, CD4, CD8, CD45RA, IFN-γ
(immune interferon). For 2 patients, CD4+ and CD8+ IFN-γ+
T cellswere sorted. DNA from the sorted PBMCs, skin lesions,
and lung tumorswas used to carry out T-cell receptor (TCR) β
sequencing (ImmunoSEQ Assays, survey resolution; Adap-
tive Biotechnologies).
Statistical Analysis
Kaplan-Meierplotsweregenerated foroverall survival andpro-
gression-free survival using the survminer package in R, ver-
sion 3.5.0 (R Foundation for Statistical Computing). The as-
sociationbetween thedevelopmentof autoimmuneskin toxic
effects and overall survival or progression-free survival was
examinedusing the log-rank test.Hazard ratios (HRs) and95%
CIs were calculated using univariate Cox proportional haz-
ards regression model with the survival package in R; we se-
lected the development of autoimmune skin toxic effects as
the covariate and overall survival or progression-free sur-
vival as the outcome. The χ2 test was used to test for associa-
tions between categorical variables.
Logistic regression was used to test the association be-
tween frequencies of IFN-γ+ T-cell response after stimula-
tionswith thepeptidepools anddevelopment of skin toxic ef-
fects. Results from 21 patients with skin toxic effects and 18
patientswithout skin toxic effectswere included in the analy-
sis. Statistical significancewas defined at the level of P = .05.
Additionalmethods informationcanbe found in theeMethods
in the Supplement.
Results
The organ-specific immune-related adverse effects analysis
revealed a statistically significant association between the
tumor-to-tissue similarity level and the frequency of auto-
immune toxic effects (Figure 1). Skin was the second most
similar organ to NSCLC (after lung) and had the second high-
est proportion of autoimmune adverse effects. Of the cohort
of 73 patients with NSCLC (mean [SD] age, 68.1 [8.9] years;
44 [60%] men), 25 (34.2% [95% CI, 24.4%-45.7%]) devel-
oped autoimmune skin toxic effects, which were more fre-
quent in patients with complete remission or partial remis-
sion (68.2% [95% CI, 47.3%-83.6%]) than those with
progressive or stable disease (19.6% [95% CI, 11.0%-32.5%])
(χ2 = 14.02, P < .001). In addition, 15 patients (68.2%; 95%
CI, 47.3%-83.6%) with complete remission or partial remis-
sion developed autoimmune skin toxic effects, compared
with only 6 patients (16.2%; 95% CI, 7.7%-31.1%) with pro-
gressive disease (χ2 = 14.06; P < .001) (eFigure 1 in the
Supplement).
A histologic analysis of lesional biopsy specimens from
sites of autoimmune skin toxic effects and lung tumors dem-
onstrated adense infiltrationof T cells (Figure 2AandB; eFig-
ure 2 in theSupplement). Computed tomographic scans taken
during therapy showed that most patients with skin toxic ef-
fectswere good responders (eFigure 3 in the Supplement). Pa-
tients with skin toxic effects also showed statistically signifi-
cantly improved overall survival (HR, 0.29 [95% CI, 0.12-
0.71]; P = .004) (Figure 2C) and progression-free survival
(HR, 0.22 [95% CI, 0.09-0.49]; P = .001) (eFigure 4 in the
Supplement). Patients who responded to therapy were more
than5 timesmore likely tohaveexperiencedautoimmuneskin
toxic effects comparedwith thosewhodid not respond (odds
ratio, 5.28 [95% CI, 1.78-15.67]; P = .003), a finding that is in
line with results of several studies, suggesting that autoim-
mune adverse effects are associated with response to
therapy.4-9
Owing to theT-cell infiltration in theaffected skin,weper-
formedaTCRclonotypeanalysiswithpatient-matchedNSCLC
and skin biopsy specimens, revealing identical TCR se-
quences in the lung tumors and the autoimmune skin lesions
Key Points
Question What are the underlying pathophysiologic processes
of autoimmune skin toxic effects induced by anti–PD-1 therapy
in patients with non–small cell lung cancer?
Findings In this cohort study of 73 patients with non–small cell
lung cancer who received anti–PD-1 therapy, T cells that reacted
to antigens shared in non–small cell lung cancers and the skin
mediated autoimmune skin toxic effects. These T cells may also
havemediated the tumor regression in patients who responded
to therapy.
Meaning Autoimmune toxic effects associated with checkpoint
blockademay serve as biomarkers for clinical responses and
provide opportunities to identify cancer T-cell targets.
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(eFigure 5 in the Supplement). This finding indicates that the
sameT-cell clonotypes infiltratedboth sites and suggests that
T cells react against shared antigens in the 2 organs.
An in silico bioinformatics analysiswas subsequentlyper-
formed to identify potential shared antigens between NSCLC
and the skin (eFigure6 in theSupplement). Tobe selected, the
Figure 1. Tissue Similarity Between Lung Tumors andOrgans Affected by Autoimmune Toxic Effects
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Positive associations between tumor-tissue similarity score and organ-specific
immune-related adverse effects in patients with non–small cell lung carcinoma
treated with nivolumab (A) or pembrolizumab (B). Pearson correlation
coefficient was R = 0.71 for nivolumab and R = 0.81 for pembrolizumab, and the
P value was P = .003 for nivolumab and P = .001 for pembrolizumab.
Figure 2. Association Between Autoimmune Skin Toxic Effects and Response to Therapy
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Images of a representative patient
show autoimmune skin toxic effects
(A) and lung tumors (B) characterized
by an inflammatory infiltrate shown
by CD3 immunohistochemistry
(magnification ×100).
C, Kaplan-Meier analysis of patients
treated with PD-1 inhibitors reveals
better outcome for 25 patients who
developed skin toxic effects (blue
line) compared with 48 other
patients who did not develop skin
toxic effects (orange line). One-year
overall survival rate was 76% in the
group with skin toxic effects and
38% in the group without skin toxic
effects, with a hazard ratio of 0.29
(95% CI, 0.12-0.71) and log-rank
P = .004.
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antigens had to fulfill the following properties: (1) evidence
of self-immunogenicity, (2) high expression in NSCLCs, and
(3) skin or lung specificity. This analysis identified 9 candi-
date T-cell antigens (eTable in the Supplement). To deter-
mine whether these antigens were recognized by antigen-
specificTcells,westimulatedPBMCsfrom21patientswithskin
toxic effects and 18patientswithout skin toxic effectswith the
antigens in the form of overlapping peptide pools. Regres-
sionanalysis revealedanassociationbetweendevelopmentof
skin toxic effects and high frequencies of IFN-γ+ T-cell re-
sponse, which was significant for CD8+ IFN-γ+ T-cell
response (odds ratio, 1.99 [95% CI, 1.01-3.90]; P = .046), but
wasnot forCD4+ IFN-γ+T-cell response (odds ratio, 1.05 [95%
CI, 0.98-1.13]; P = .146) (eFigure 7 in the Supplement). The
stimulated IFN-γ+ T cellswere sorted from thePBMCsof 2 pa-
tients with skin toxic effects and who showed response to
therapy. TheTCRs of the sorted IFN-γ+ T cellswere then com-
pared with the TCRs found in the NSCLC and skin toxic ef-
fects from the samepatients. Identical antigen-specific T cells
were found in the patients’ PBMCs and tissues, with some
clonesbeingpresent inall 3compartments.For 1patient, shared
T-cell clones were found specific for desmocollin 3 and kera-
tin 6 (Figure 3A), whereas for another patient, shared T-cell
clones were found specific for maspin, LL37, keratin 14, and
desmocollin 3 (Figure 3B).
Discussion
Several studies report an association between immune-
related adverse effects and response to treatmentwith check-
point inhibitors in patients withmelanoma.4,5,8 This associa-
tion also has been hypothesized in patients with NSCLC.6,7,9
To our knowledge, the present study is the first to show a po-
tentialmechanismof checkpoint inhibitor–mediated autoim-
mune skin toxic effects and to describe the association be-
tween immune-relatedadverseeffects and treatmentefficacy.
This study suggests that, during checkpoint inhibitor therapy,
T cells recognizing shared lung tumor and skin antigens si-
multaneously target both organs. This process is associated
with the development of autoimmune skin toxic effects and
likely with tumor regression as well. A similar association is
seen in patients with melanoma treated with anti–PD-1, in
which good responders to therapy often develop a skin con-
dition known as vitiligo.10
The identification of antigens shared between tumors
and healthy tissues may provide a dual advantage: (1) it helps
in anticipating autoimmune toxic effects, and (2) it reveals
potential new tumor targets. For effective cancer immuno-
therapy, many currently favor neoantigens. However, not all
tumors harbor potent neoantigens, and tissue-specific anti-
gens can, in principle, also support strong antitumor T-cell
responses, with autoimmunity as an adverse effect, as shown
in this study. Therefore, it may be necessary to identify
shared antigens able to mediate tumor rejection with only
limited toxic effects.
Limitations
This study has limitations. First, the sample size is small.
Second, we used a limited number of matched non–small
cell lung cancer and skin specimens for the TCR clonotype
analysis.
Figure 3. Sharing of T-Cell Clones in Autoimmune Skin Lesions, Lung Tumors, and Antigen-Stimulated Peripheral BloodMononuclear Cells (PBMCs)
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A, TCRβ sequences shared in the non–small cell lung carcinoma (NSCLC), skin,
and sorted CD4+/CD8+ interferon (IFN)-γ+ T cells from PBMCs after the latter
were stimulated with desmocollin 3 (DSC3) and keratin 6 (KRT6) from 1 patient.
In total, 5 unique shared clones were found. The CD4+ clones shared with
PBMCs are encircled in orange, and CD8+ clones shared with PBMCs are
encircled in dark blue in the dot plots. B, Shared TCRβ sequences in the NSCLC,
skin, and sorted CD4+/CD8+ IFN-γ+ T cells from PBMCs after the latter were
stimulated with maspin, LL37, keratin 14 (KRT14), and DSC3 from another
patient. In total, 31 unique shared clones were found (for this patient, only some
of the clones are indicated).
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Conclusions
This studysuggests that specific autoimmuneT-cell clones rec-
ognize shared self-antigens in lung cancer and the skin. These
T-cell clonesmaymediate theautoimmuneskin toxiceffects in
patientswithNSCLCwhoreceiveanti–PD-1therapyaswellasthe
lungcancer regression inpatientswhorespondwell to therapy.
If thishypothesiscanbeproveninlargerprospectivecohorts, rel-
evantantigen-specificTcellsmaybeusefulaspotentialbiomark-
ersofresponsetotreatment.Combinedwithappropriatepatient
selection, this knowledgemayhelp improve theefficacyof im-
munotherapyandanticipate itsassociatedautoimmunetoxicef-
fects, thereby fostering its clinical application.
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